Toll-like receptor 9 expression in the natural history of Barrett mucosa
- PMID: 25838081
- DOI: 10.1007/s00428-015-1770-3
Toll-like receptor 9 expression in the natural history of Barrett mucosa
Abstract
Increased expression of TLR9 in esophageal adenocarcinoma and squamous cell carcinoma correlates with poor prognosis. We have explored the expression and suspected that TLR9 activation might contribute to pathogenesis in esophageal columnar metaplasia-dysplasia-neoplasia sequence, and hence, we have studied the usefulness of TLR9 as a marker for dysplasia. We have determined the expression of TLR9 in specimens with normal esophagus (n = 89), gastric (n = 71), or intestinal metaplasia (n = 56) without dysplasia, and low-grade (n = 51) or high-grade dysplasia (n = 40), and esophageal adenocarcinoma (n = 88). We observed linearly increasing TLR9 expression in specimens to be associated with change from normal epithelium to columnar metaplasia and further to dysplasia. ROC curve analysis showed clinically irrelevant sensitivity of 71% and specificity of 67% for TLR9 intensity in detection of low-grade dysplasia. Membrane-associated TLR9 expression detected by immunohistochemistry and immunofluorescence was predominantly associated with foveolar-type dysplasia as detected by HE staining (p = 0.015). TLR9 is expressed in Barrett's esophagus, and dissolution of TLR9 staining increases from nondysplastic epithelium to dysplastic. TLR9 may serve as a new way of recognizing the histopathological origin of dysplasia (adenomatous vs foveolar) with observed subcellular pattern of TLR9.
Similar articles
-
Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma.Oncotarget. 2016 Apr 26;7(17):23658-67. doi: 10.18632/oncotarget.8151. Oncotarget. 2016. PMID: 27008696 Free PMC article.
-
Divergent expression of MUC5AC, MUC6, MUC2, CD10, and CDX-2 in dysplasia and intramucosal adenocarcinomas with intestinal and foveolar morphology: is this evidence of distinct gastric and intestinal pathways to carcinogenesis in Barrett Esophagus?Am J Surg Pathol. 2012 Mar;36(3):331-42. doi: 10.1097/PAS.0b013e31823d08d6. Am J Surg Pathol. 2012. PMID: 22261707
-
Increased Toll-like receptor 5 expression indicates esophageal columnar dysplasia.Virchows Arch. 2014 Jan;464(1):11-8. doi: 10.1007/s00428-013-1505-2. Epub 2013 Nov 13. Virchows Arch. 2014. PMID: 24221343
-
The diagnosis and management of Barrett's esophagus.Adv Surg. 1999;33:29-68. Adv Surg. 1999. PMID: 10572561 Review.
-
The Role of Toll-like Receptors in Esophageal Cancer.Anticancer Res. 2022 Jun;42(6):2813-2818. doi: 10.21873/anticanres.15762. Anticancer Res. 2022. PMID: 35641301 Review.
Cited by
-
Divergent expression of bacterial wall sensing Toll-like receptors 2 and 4 in colorectal cancer.World J Gastroenterol. 2017 Jul 14;23(26):4831-4838. doi: 10.3748/wjg.v23.i26.4831. World J Gastroenterol. 2017. PMID: 28765705 Free PMC article.
-
Intratumoral lactate metabolism in Barrett's esophagus and adenocarcinoma.Oncotarget. 2017 Apr 4;8(14):22894-22902. doi: 10.18632/oncotarget.15284. Oncotarget. 2017. PMID: 28206968 Free PMC article.
-
Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma.Oncotarget. 2016 Apr 26;7(17):23658-67. doi: 10.18632/oncotarget.8151. Oncotarget. 2016. PMID: 27008696 Free PMC article.
-
The Expression of Toll-like Receptors in Normal Human and Murine Gastrointestinal Organs and the Effect of Microbiome and Cancer.J Histochem Cytochem. 2016 Aug;64(8):470-82. doi: 10.1369/0022155416656154. Epub 2016 Jul 1. J Histochem Cytochem. 2016. PMID: 27370795 Free PMC article.
-
High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients.Virchows Arch. 2017 Apr;470(4):401-410. doi: 10.1007/s00428-017-2087-1. Epub 2017 Feb 12. Virchows Arch. 2017. PMID: 28191612
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources